Sanofi gets binding bids for consumer unit
Banks and other lenders are readying over €10B ($11.1B) in funding as New York-based buyout firm Clayton Dubilier & Rice and ...
After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.
Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...
Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
As Poland prepares for its EU Presidency, health needs to be a major focus, given its crucial role in Europe's prosperity and global competitiveness. Predictable pharmaceutical legislation is essentia ...
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...
1d
Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on Sanofi (SNYNF – Research Report) and increased the price target ...
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback